Basilea Pharmaceutica AG provided financial guidance for the full-year 2019. The company narrows its previous guidance on total revenue to CHF 128-133 million, reflecting lower than previously anticipated BARDA revenue based on lower R&D expenses incurred related to the ceftobiprole phase 3 program. Total cost and operating expenses are expected to remain at approximately the same level as 2018, leading to an anticipated operating loss of CHF 22-27 million for 2019.